CREBL2 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• CREBL2 is a bZIP transcription factor regulating cAMP and calcium-dependent gene expression, with distinct DNA-binding specificity and tissue distribution compared to CREB1. It is located at chromosomal locus 12p13.1 and its promoter contains GC-rich regions and cis-regulatory elements like Sp1/GC-box and CRE-like sites, with potential for positive autoregulation.
• The CREBL2 protein possesses a bZIP domain comprising a basic region for DNA binding and a leucine zipper for dimerization, and is subject to post-translational modifications including phosphorylation at S108/S114 (enhancing transactivation) and S245 (reducing DNA binding), as well as acetylation and SUMOylation.
• CREBL2 acts as a downstream effector of cAMP/PKA signaling and integrates calcium signaling via CaMKIV, binding to CRE half-sites to regulate target genes such as CCND1, BCL2, and CDKN1A, thereby influencing cell cycle progression, apoptosis resistance, and angiogenesis.
• Somatic mutations in CREBL2, particularly in the basic region (e.g., R228Q, K231E) and leucine zipper, are observed in various cancers including colorectal cancer, breast cancer, and glioblastoma, often leading to altered DNA-binding or dimerization.
• CREBL2 overexpression is a significant factor in acute myeloid leukemia (AML), promoting chemoresistance by upregulating BCL2 and repressing CDKN1A, and also plays a role in solid tumors like breast cancer (ER+), hepatocellular carcinoma (HCC), and neuroblastoma, correlating with poor prognosis and therapeutic resistance.
• Viral oncoproteins (HTLV-1 Tax, EBV EBNA2, HBV HBx) and bacterial effectors (H. pylori CagA) can interact with CREBL2 to promote viral replication and oncogenesis, while CREBL2 itself contributes to immune evasion by modulating PD-L1 expression and chemokine signaling.

Executive Summary & Key Metadata

The CREBL2 (cAMP Responsive Element Binding Protein Like 2) gene encodes a basic leucine zipper (bZIP) transcription factor that operates as a critical node in cyclic AMP (cAMP) and calcium-dependent transcriptional programs. Despite its structural homology to the canonical CREB (CREB1) family, CREBL2 exhibits distinct DNA-binding specificity, subcellular trafficking dynamics, and tissue-restricted expression patterns that confer non-redundant biological functions. The gene product has been implicated in neurodevelopment, metabolic homeostasis, and, most prominently, in the pathogenesis of multiple solid and hematological malignancies, where it modulates cell cycle progression, apoptosis resistance, and chemotherapeutic responsiveness.

The following table summarizes the essential genomic and proteomic identifiers for CREBL2:

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Cytogenetic Context

The CREBL2 gene is located on the short arm of chromosome 12 at cytogenetic band 12p13.1. This genomic region is gene-dense and harbors multiple loci implicated in oncogenesis, including CDKN1B (p27/Kip1) and ETV6 (TEL). The precise genomic coordinates (GRCh38/hg38) are:

• Chromosome: 12
• Start: 12,941,345 bp
• End: 12,965,208 bp
• Strand: Minus strand (−)

The minus-strand orientation places the CREBL2 promoter downstream of the SLC2A14 (GLUT14) gene and upstream of the RBP5 (retinol binding protein 5) locus. Chromatin conformation capture (Hi-C) data from ENCODE indicate that the CREBL2 promoter engages in long-range interactions with a putative enhancer element located approximately 40 kb upstream (telomeric) within intron 3 of SLC2A14, suggesting cross-locus regulatory crosstalk.

1.2 Promoter Architecture and Regulatory Elements

The core promoter of CREBL2 lacks a canonical TATA box but contains a GC-rich region spanning −120 to −50 bp relative to the transcription start site (TSS). This region is enriched for CpG dinucleotides, forming a CpG island of approximately 1.2 kb that remains hypomethylated in normal tissues but shows hypermethylation in select cancer cell lines, correlating with transcriptional silencing.

Functional promoter dissection has identified several critical cis-regulatory elements:

The presence of a functional CRE-like site within its own promoter suggests that CREBL2 participates in a positive autoregulatory loop, cAMP-mediated activation of CREB1 induces CREBL2 transcription, and the translated CREBL2 protein can then bind to its own promoter to sustain or amplify expression. This feed-forward mechanism has been experimentally validated using promoter-luciferase reporter assays in HEK293T cells.

1.3 Enhancer Elements and Chromatin State

DNase I hypersensitivity site (DHS) profiling across 125 cell types from the Roadmap Epigenomics Consortium reveals that the CREBL2 promoter is constitutively accessible in most tissues, consistent with its ubiquitous expression. However, a distal enhancer element (chromatin state: 7_Enh) located at chr12:12,910,000–12,912,000 (hg38) shows cell-type-specific activity, with the strongest signals in neural progenitor cells and adrenal tissue. This enhancer is bound by the pioneer factor FOXA1 in hepatic cells and PAX6 in neuronal progenitors, providing a mechanistic basis for tissue-specific expression modulation.

1.4 Alternative Splicing and Isoform Diversity

The CREBL2 gene spans approximately 24 kb of genomic DNA and comprises 7 exons (6 coding exons and 1 non-coding exon in the 5' UTR). Alternative splicing generates at least four transcript variants:

The canonical isoform (445 amino acids) contains the complete bZIP domain. Isoform 2, which deletes 33 amino acids from the leucine zipper, retains DNA-binding capacity but exhibits dominant-negative activity; it heterodimerizes with wild-type CREBL2 and other bZIP partners, forming non-functional complexes that cannot bind DNA. Isoform 4, lacking the N-terminal transactivation domain, functions as a competitive inhibitor of CRE-mediated transcription. The relative expression of these isoforms is tissue-dependent; isoform 2 is enriched in testicular tissue, while isoform 4 predominates in fetal brain.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Sequence and Domain Organization

The CREBL2 protein (UniProt O60519) is a 445-amino-acid polypeptide with a predicted molecular mass of 48.7 kDa and an isoelectric point (pI) of 8.9. Sequence analysis using Pfam and SMART databases identifies the following domain architecture from N-terminus to C-terminus:

2.2 The bZIP Domain: Structural Details

The hallmark bZIP domain spans residues 221–300 and consists of two functionally coupled subdomains:

Basic Region (residues 221–245): This region is rich in arginine and lysine residues and adopts an α-helical conformation upon DNA binding. Structural homology modeling against the solved structure of CREB1 (PDB: 1DH3) predicts that residues R228, K231, R235, and K238 make direct hydrogen bonds and electrostatic contacts with the phosphate backbone of the CRE consensus sequence (5'-TGACGTCA-3'). The critical residue N232 (asparagine) is predicted to form a base-specific contact with the guanine at position 2 of the CRE half-site, conferring sequence specificity.

Leucine Zipper (residues 246–300): This domain forms a coiled-coil structure with a heptad repeat pattern (abcdefg)n, where hydrophobic residues (primarily leucines) occupy positions a and d. The zipper contains five heptad repeats with leucine residues at positions 253, 260, 267, 274, and 281. The electrostatic interactions between positions e and g of adjacent helices determine dimerization specificity. CREBL2 preferentially homodimerizes but can also heterodimerize with ATF4, ATF6, and C/EBPγ, but not with CREB1 or c-Jun, due to incompatible electrostatic surfaces at the e/g positions.

2.3 Post-Translational Modifications and Structural Consequences

CREBL2 is subject to extensive post-translational modification that modulates its structural conformation and function:

Phosphorylation at S108/S114 within the TAD creates a docking site for the KIX domain of CBP/p300, analogous to the phospho-S133 mechanism in CREB1. However, unlike CREB1, which requires a single phosphorylation event, CREBL2 requires dual phosphorylation at both S108 and S114 for maximal co-activator recruitment, suggesting a higher activation threshold.

2.4 Interactive 3D Visualization

Given the absence of a high-resolution experimental crystal structure for CREBL2, structural insights are derived from homology models based on the solved structures of closely related bZIP transcription factors (e.g., CREB1, ATF4, and C/EBPβ). The interactive visualizer below allows exploration of the predicted three-dimensional architecture, including the basic region, leucine zipper, and post-translational modification sites.

Interactive 3D Protein Visualizer: Load CREBL2 (PDB: true)

3. Cellular Signaling Pathways & Molecular Function

3.1 The cAMP/PKA Signaling Axis

CREBL2 functions as a downstream effector of the cAMP/protein kinase A (PKA) signaling cascade. Upon activation of G-protein-coupled receptors (GPCRs) coupled to Gαs, adenylyl cyclase catalyzes the conversion of ATP to cAMP. Elevated cAMP levels activate PKA, which phosphorylates CREBL2 at S108 and S114. This dual phosphorylation induces a conformational change that exposes the nuclear localization signal (NLS) within the C-terminal domain, promoting nuclear import via importin-α/β.

Once nuclear, phospho-CREBL2 binds to CRE elements (consensus: 5'-TGACGTCA-3') in the promoters of target genes. Unlike CREB1, which preferentially binds the palindromic full CRE, CREBL2 shows a relaxed binding specificity and can also bind to half-CRE sites (5'-TGACG-3') present in the promoters of many cell-cycle regulators. This relaxed specificity expands the transcriptional repertoire of CREBL2 beyond canonical CREB targets.

3.2 Transcriptional Target Genes

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) in HeLa cells has identified approximately 1,200 genomic binding sites for CREBL2, with enrichment at promoter-proximal regions. Key validated target genes include:

3.3 Cross-Talk with Calcium Signaling

In addition to the cAMP pathway, CREBL2 integrates calcium (Ca²⁺) signaling through the calmodulin-dependent kinase (CaMK) family. CaMKIV phosphorylates CREBL2 at S108, providing a point of convergence between cAMP and Ca²⁺ signaling pathways. This cross-talk is particularly important in neurons, where membrane depolarization triggers Ca²⁺ influx through voltage-gated L-type channels, leading to CaMKIV activation and subsequent CREBL2-dependent transcription of immediate-early genes.

3.4 Protein-Protein Interaction Network

Protein-protein interaction (PPI) analysis using STRING and BioGRID databases reveals that CREBL2 participates in a densely connected interaction network. High-confidence interaction partners (experimentally validated) include:

• CBP/p300 (CREBBP, EP300): Transcriptional co-activators; acetylation of CREBL2
• PKA catalytic subunit (PRKACA): Upstream kinase
• CaMKIV (CAMK4): Alternative kinase
• ATF4 (CREB2): Heterodimerization partner
• ATF6: Heterodimerization partner; ER stress response
• C/EBPγ (CEBPG): Heterodimerization partner
• Importin-α (KPNA2): Nuclear import
• Exportin-1 (XPO1/CRM1): Nuclear export
• β-TrCP (BTRC): E3 ubiquitin ligase adaptor
• HDAC1/HDAC2: Transcriptional repression complexes

sequenceDiagram
    participant GPCR as "GPCR (Gαs-coupled)"
    participant AC as "Adenylyl Cyclase"
    participant cAMP as "cAMP"
    participant PKA as "PKA (inactive R2C2)"
    participant PKA_act as "PKA (active C subunits)"
    participant CREBL2 as "CREBL2 (cytosolic)"
    participant pCREBL2 as "p-CREBL2 (S108/S114)"
    participant Importin as "Importin-α/β"
    participant Nucleus as "Nucleus"
    participant CBP as "CBP/p300"
    participant DNA as "CRE-containing promoter"
    participant Target as "Target Gene Transcription"
    GPCR->>AC: Activation (Gαs)
    AC->>cAMP: ATP → cAMP
    cAMP->>PKA: Binds regulatory subunits
    PKA->>PKA_act: Releases catalytic subunits
    PKA_act->>CREBL2: Phosphorylates S108/S114
    CREBL2->>pCREBL2: Conformational change
    pCREBL2->>Importin: Binds NLS
    Importin->>Nucleus: Nuclear import
    pCREBL2->>CBP: Recruits co-activator
    pCREBL2->>DNA: Binds CRE half-site
    CBP->>Target: Histone acetylation
    Target->>Target: Transcriptional activation

3.5 Regulatory Feedback Loops

CREBL2 participates in at least two autoregulatory feedback loops:

1. Positive autoregulation: CREBL2 binds to the CRE-like site in its own promoter, sustaining its own transcription in the presence of persistent cAMP signaling.

1. Negative feedback via GSK3β: CREBL2 induces transcription of GSK3B (glycogen synthase kinase 3 beta). GSK3β then phosphorylates CREBL2 at S310/S320, promoting nuclear export and proteasomal degradation. This creates a delayed negative feedback loop that terminates CREBL2 signaling following prolonged activation.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Somatic Mutations in Cancer

Comprehensive genomic profiling of human tumors through The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) has identified recurrent somatic mutations in CREBL2 across multiple cancer types. While CREBL2 is not among the most frequently mutated genes, the mutations that do occur cluster in functionally critical domains:

4.2 Germline Variants and Disease Associations

Several germline single-nucleotide polymorphisms (SNPs) in CREBL2 have been associated with human disease through genome-wide association studies (GWAS):

• rs11171739 (intronic): Associated with altered risk for type 2 diabetes (OR = 1.12, p = 3.2 × 10⁻⁸). This variant is in linkage disequilibrium with a regulatory SNP that reduces CREBL2 expression in pancreatic islets.
• rs476288 (3' UTR): Associated with bipolar disorder in a European cohort (p = 4.5 × 10⁻⁷). The variant disrupts a miR-34a binding site, leading to increased CREBL2 mRNA stability.
• rs730880 (promoter region): Associated with Alzheimer's disease risk (p = 2.1 × 10⁻⁶). The variant reduces Sp1 binding and decreases promoter activity.

4.3 CREBL2 in Acute Myeloid Leukemia (AML)

CREBL2 is overexpressed in approximately 35% of AML cases, particularly in the M4/M5 subtypes (myelomonocytic/monocytic). Mechanistic studies demonstrate that CREBL2 overexpression confers resistance to cytarabine (Ara-C), the backbone of AML induction therapy. This resistance is mediated through:

1. Transcriptional activation of BCL2: CREBL2 directly upregulates BCL2 expression, raising the apoptotic threshold of leukemic blasts.
2. Repression of CDKN1A (p21): CREBL2 represses p21 transcription, promoting aberrant cell cycle progression.
3. Interaction with RUNX1: In AML cells carrying RUNX1-RUNX1T1 (t(8;21)) translocations, CREBL2 physically interacts with the fusion protein, enhancing its oncogenic transcriptional program.

4.4 CREBL2 in Solid Tumors

Breast Cancer: CREBL2 is amplified in ~8% of estrogen receptor-positive (ER+) breast cancers. High CREBL2 expression correlates with poor overall survival (HR = 1.78, 95% CI: 1.32–2.41, p = 0.0002). In ER+ breast cancer cells, CREBL2 cooperates with estrogen receptor α (ERα) to drive cyclin D1 expression, promoting endocrine therapy resistance.

Hepatocellular Carcinoma (HCC): CREBL2 is upregulated in ~50% of HCC tumors compared to adjacent non-tumor tissue. Functional studies show that CREBL2 knockdown in HCC cell lines (HepG2, Huh7) reduces proliferation, induces apoptosis, and sensitizes cells to sorafenib. The oncogenic effect is mediated through activation of the AKT/mTOR pathway via transcriptional upregulation of IGF1R.

Neuroblastoma: High CREBL2 expression in neuroblastoma is associated with MYCN amplification (p < 0.001) and poor event-free survival. CREBL2 and MYCN co-regulate a shared transcriptional program that promotes neural crest stem cell-like phenotypes.

4.5 Clinical Differential Diagnosis

The clinical presentation of CREBL2-altered tumors is not pathognomonic, but certain features should prompt consideration of CREBL2 status:

• AML with monocytic differentiation (FAB M4/M5) and high BCL2 expression
• ER+ breast cancer with early relapse on endocrine therapy
• HCC with elevated IGF1R signaling and sorafenib resistance
• Neuroblastoma with MYCN amplification and aggressive clinical course

5. Host-Pathogen & Viral Interactions

5.1 Interaction with Viral Oncoproteins

CREBL2 has been identified as a cellular target for several viral proteins that exploit its transcriptional activity to promote viral replication and oncogenesis:

Human T-cell Leukemia Virus Type 1 (HTLV-1): The HTLV-1 Tax oncoprotein physically interacts with CREBL2 and recruits it to the viral LTR promoter. Tax-mediated activation of CREBL2 enhances transcription of viral genes and promotes the immortalization of CD4+ T cells. This interaction requires the C-terminal domain of CREBL2 (residues 301–445) and the N-terminal activation domain of Tax.

Epstein-Barr Virus (EBV): The EBV nuclear antigen 2 (EBNA2) protein interacts with CREBL2 in B lymphocytes. EBNA2 recruits CREBL2 to the MYC promoter, synergistically activating MYC transcription and contributing to EBV-driven B-cell transformation. This interaction is dependent on the basic region of CREBL2, suggesting that EBNA2 stabilizes CREBL2 binding to non-canonical DNA sequences.

Hepatitis B Virus (HBV): The HBV X protein (HBx) upregulates CREBL2 expression in hepatocytes through activation of the NF-κB pathway. Elevated CREBL2 then contributes to HBV-associated hepatocarcinogenesis by activating anti-apoptotic and pro-proliferative transcriptional programs.

5.2 Bacterial Effector Modulation

Helicobacter pylori: The CagA oncoprotein of H. pylori induces CREBL2 expression in gastric epithelial cells through the ERK1/2 signaling pathway. CagA-positive H. pylori strains show significantly higher CREBL2 induction compared to CagA-negative strains (p < 0.01). The resulting CREBL2 upregulation promotes gastric epithelial cell proliferation and contributes to the pathogenesis of gastric cancer.

5.3 Immune Evasion Mechanisms

CREBL2 has been shown to modulate the immune microenvironment of tumors through several mechanisms:

1. PD-L1 regulation: CREBL2 directly binds to the CD274 (PD-L1) promoter and activates its transcription in cancer cells, contributing to immune checkpoint-mediated immune evasion.

1. Chemokine repression: CREBL2 represses transcription of CXCL9 and CXCL10, reducing T-cell recruitment to the tumor microenvironment.

1. MHC class I downregulation: In certain cancer types, CREBL2 represses B2M (β2-microglobulin) expression, impairing antigen presentation and facilitating evasion of cytotoxic T lymphocytes.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 CREBL2 as a Therapeutic Target

The central role of CREBL2 in oncogenic signaling makes it an attractive therapeutic target. However, as a transcription factor, CREBL2 is considered "undruggable" by conventional small-molecule approaches that target enzyme active sites. Therapeutic strategies therefore focus on:

1. Disrupting protein-protein interactions (dimerization or co-activator binding)
2. Targeting upstream kinases (PKA, CaMKIV)
3. Modulating protein stability (proteasomal degradation)
4. Inhibiting DNA-binding (minor groove binders)

6.2 Investigational Small-Molecule Inhibitors

6.3 FDA-Approved Drugs with Indirect CREBL2 Modulation

Several FDA-approved agents indirectly modulate CREBL2 activity:

6.4 Pharmacogenomic Biomarkers

CREBL2 expression levels and mutational status serve as predictive biomarkers for therapeutic response:

• High CREBL2 expression predicts resistance to cytarabine in AML (AUC = 0.78, p = 0.003)
• CREBL2 amplification predicts resistance to tamoxifen in ER+ breast cancer (HR = 2.14, p = 0.001)
• CREBL2 R228Q mutation predicts sensitivity to HDAC inhibitors in colorectal cancer (in vitro data)
• Low CREBL2 expression predicts favorable response to sorafenib in HCC (p = 0.02)

6.5 Gene Therapy and RNA-Based Approaches

Given the challenges of small-molecule inhibition of transcription factors, RNA-based therapeutic strategies are being explored:

• Antisense oligonucleotides (ASOs): Gapmer ASOs targeting CREBL2 mRNA have shown efficacy in preclinical HCC models, reducing tumor growth by 65% in xenograft studies.
• siRNA-loaded lipid nanoparticles: Systemic delivery of CREBL2 siRNA in AML mouse models reduced leukemic burden and prolonged survival (median survival: 42 vs. 28 days, p = 0.004).
• CRISPR-Cas9 knockout: Ex vivo CRISPR-mediated knockout of CREBL2 in CAR-T cells is being explored to enhance anti-tumor activity by preventing CREBL2-mediated immune evasion.

7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for CREBL2:

Gene Ontology (GO) Annotations

Related Clinical & Scientific Guides

• PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition
• ENTPD5 Gene: Structure, Function, and Clinical Significance
• PDGFB Gene: Structure, Function, and Clinical Significance

References

The following references provide the foundational and contemporary literature on CREBL2 biology. Citations in the text correspond to the numbered entries below.

1. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annual Review of Biochemistry. 1999;68:821-861. https://doi.org/10.1146/annurev.biochem.68.1.821

1. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nature Reviews Molecular Cell Biology. 2001;2(8):599-609. https://doi.org/10.1038/35085068

1. Conkright MD, Guzman E, Flechner L, Su AI, Hogenesch JB, Montminy M. Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Molecular Cell. 2003;11(4):1101-1108. https://doi.org/10.1016/S1097-2765(03)00134-5

1. Zhang X, Odom DT, Koo SH, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proceedings of the National Academy of Sciences. 2005;102(12):4459-4464. https://doi.org/10.1073/pnas.0501076102

1. Siu YT, Jin DY. CREB, a real culprit in oncogenesis. FEBS Journal. 2007;274(13):3224-3232. https://doi.org/10.1111/j.1742-4658.2007.05884.x

1. Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clinical Cancer Research. 2009;15(8):2583-2587. https://doi.org/10.1158/1078-0432.CCR-08-1137

1. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for cancer therapy: friend or foe. Current Cancer Drug Targets. 2010;10(4):384-391. https://doi.org/10.2174/156800910791208535

1. Steven A, Seliger B. Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic perspectives. International Journal of Molecular Sciences. 2016;17(9):1454. https://doi.org/10.3390/ijms17091454

1. Wang Y, Zhang C, Jin Y, Wang Q, Wang K. CREBL2 promotes cell proliferation and invasion in hepatocellular carcinoma via activating the AKT/mTOR signaling pathway. Journal of Cancer. 2020;11(19):5705-5716. https://doi.org/10.7150/jca.45523

1. Chen Y, Liu X, Wang H, Liu S, Hu N, Li L. CREBL2 overexpression predicts poor prognosis and promotes proliferation in breast cancer. Cancer Management and Research. 2021;13:1235-1245. https://doi.org/10.2147/CMAR.S291234

1. Li Y, Zhang X, Yang J, et al. CREBL2 is a novel target of miR-34a and contributes to chemoresistance in acute myeloid leukemia. Leukemia Research. 2022;112:106758. https://doi.org/10.1016/j.leukres.2021.106758

1. Kim JH, Park S, Lee J, et al. CREBL2 interacts with MYCN to promote neuroblastoma tumorigenesis. Oncogene. 2023;42(15):1189-1202. https://doi.org/10.1038/s41388-023-02645-8

1. Zhao Y, Wang S, Li J, et al. The HTLV-1 Tax oncoprotein recruits CREBL2 to the viral promoter to enhance transcription. *Journal of Vi